A serious push into the US market is a key strategic target for the merged Standard Life and Aberdeen Asset Management group, according to Aberdeen’s global head of distribution.
The UK government’s shock decision to impose a 25% charge on transfers to foreign pension schemes announced in the Spring Budget could go as far as to "shut down" the Qrops market, according to industry observers.
The funds business in Guernsey is now worth £227.6bn ($323.7bn, €288.2bn) – a year-on-year increase of £8.2bn in net asset value, data from the Guernsey Financial Services Commission (GFSC) has revealed.
American expats should not renounce their citizenship because of FATCA without considering all of their options, according to Nigel Green, chief executive and founder of deVere Group.
Ashmore has unveiled three China-focussed funds that aim to invest in China's onshore equity and fixed income markets using its RMB Qualified Foreign Institutional Investor (RQFII) license.
Matthews Asia has launched a new strategic income fund, as an expansion of its Luxembourg-domiciled UCITS fund range.
Jupiter Asset Management has announced a distribution agreement with NASDAQ OMXs Nordic Fund Market as it seeks to expand its presence in the region.
American asset management firm Fred Alger Management has launched two funds via its recently established Luxembourg SICAV, the third vehicle it has made available to non-US investors.
Investment research analyst at Morningstar, Michael Eyre, reveals his top three global bond funds to keep an eye on.
Petrus Financial Services will now have access to two of Brooks Macdonald Asset Managements offshore bond compatible portfolio services as part of a newfound strategic alliance.
Lombard Odier Investment Managers (LOIM) has launched a US-focused equity fund which aims to provide investors with an absolute return in all conditions.
Lazard Asset Management has launched the Global Controlled Volatility Fund, a long-only strategy designed to achieve market-like returns with 20% to 40% less volatility than its benchmark.
Political talk has cast a shadow over biotech stock prices. And yet the sector has...